DUBLIN--(BUSINESS WIRE)--The "Synovial Sarcoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.
Synovial sarcoma is rare type of cancer and approximately one to three people in every million people are diagnosed with synovial sarcoma every year, globally.
The disease occurs frequently in young adults; however, the disease can affect people at any age. Synovial sarcoma is more common in males, and the ratio of the disease stands at 12 males for every ten females. Synovial sarcoma often begins in the legs or arms; however, it can affect any area of the body. The disease is categorized in different subtypes based on microscopic examination or the specific gene mutation involved in the disease.
In 50% of cases, synovial sarcoma spreads to other parts of the body. The symptoms of synovial sarcoma generally vary based on the location of tumor and mainly comprise of pain and hindrance of bodily function by the mass of the tumor. For example, synovial sarcoma may hinder swallowing and breathing or it may change the voice tone in the head and neck area. In body regions where, nerves are involved the tumors can be painful.
In around 10% of cases, synovial sarcoma tumor cells move from the site of origin to a second site (metastatic). These metastases often develop in the lungs. The risk factors for synovial sarcoma have not been established till date.
Synovial Sarcoma Therapeutics Pipeline Analysis
- Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.
Scope for Customization
- Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Key Topics Covered:
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. Synovial Sarcoma Therapeutics Pipeline Analysis By Phase (2017)
6 Competitive Landscape
7 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/hsjdb8/synovial_sarcoma